

Ref. No: 1442
Date: 08/01/25
Subject: Biologics (Dermatology)

REQUEST & RESPONSE

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

• Adalimumab – Humira	13
• Adalimumab Biosimilar	142
• Apremilast	66
• Bimekizumab	0
• Brodalumab	0
• Certolizumab	0
• Deucravacitinib	0
• Dimethyl fumarate	8
• Etanercept – Enbrel	0
• Etanercept Biosimilar	<5
• Guselkumab	36
• Infliximab – Remicade	0
• Infliximab Biosimilar	0
• Ixekizumab	17
• Risankizumab	34
• Secukinumab	19
• Tildrakizumab	0
• Ustekinumab	22
• Ustekinumab Biosimilar	8
• Omalizumab	19

Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

• Adalimumab – Humira	0
• Adalimumab Biosimilar	0

• Bimekizumab	0
• Certolizumab	0
• Infliximab – Remicade	0
• Infliximab Biosimilar	0
• Secukinumab	0
• Ustekinumab	0
• Ustekinumab Biosimilar	0

<5

Due to the low number of patients receiving the some of the above medications which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).

If the requestor or any other member of the general public can, on the balance of probabilities, identify individuals by cross-referencing the anonymised data with other information that was available to them, then the information is personal data and exempt from disclosure under the Act.